Here are the 10-K annual reports from Myomo Inc. (MYO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MYO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MYO filings page.
Myomo, Inc. filed an amendment to its 2025 annual report to add detailed Part III disclosures and correct dates on executive certifications. The update focuses on board structure, committee responsibilities, executive and director compensation, stock ownership and related-party financing transactions, but does not modify previously reported financial results.
The filing describes a six-member classified board with a lead independent director, four standing committees, and a code of business conduct. It details 2025 pay for the CEO, CFO and Chief Medical Officer, including salary, RSUs and performance bonuses, and outlines severance and change-in-control protections. It also discloses major shareholders, insider participation in 2024 equity offerings and fees paid to external auditors.
Myomo, Inc. is a wearable medical robotics company focused on its MyoPro myoelectric upper-limb orthosis, sold mainly through direct billing to patients and their insurers. Revenue grew 26% in 2025 as the company improved cycle times and moved more units from authorization to delivery within each period.
The reimbursement pipeline reached 1,528 patients as of December 31, 2025, up 10% year over year, while backlog declined to 199 MyoPro units, down 27% as cases converted to revenue. Myomo relies heavily on Medicare: patients with Medicare Part B accounted for 54% of total revenue in 2025, and Medicare Advantage plans 20% of product revenue.
CMS pays lump-sum fees under brace codes L8701 and L8702, with 2026 schedule amounts of about $34,970 for Motion W and $68,800 for Motion G. Despite revenue growth, Myomo reported a 2025 net loss of $15.6 million versus $6.2 million in 2024, with an accumulated deficit of about $118.1 million and $18.4 million of cash, cash equivalents and short-term investments at year-end. As of March 2, 2026, 38,511,715 shares of common stock were outstanding.